1. Home
  2. LSCC vs INCY Comparison

LSCC vs INCY Comparison

Compare LSCC & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lattice Semiconductor Corporation

LSCC

Lattice Semiconductor Corporation

HOLD

Current Price

$119.10

Market Cap

17.2B

Sector

Technology

ML Signal

HOLD

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$122.12

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LSCC
INCY
Founded
1983
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Commercial Physical & Biological Resarch
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.2B
17.0B
IPO Year
1994
1994

Fundamental Metrics

Financial Performance
Metric
LSCC
INCY
Price
$119.10
$122.12
Analyst Decision
Strong Buy
Buy
Analyst Count
12
21
Target Price
$103.75
$103.52
AVG Volume (30 Days)
1.2M
1.1M
Earning Date
05-04-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
4173.33
EPS
0.29
1.47
Revenue
$385,961,000.00
$3,394,635,000.00
Revenue This Year
$36.12
$10.44
Revenue Next Year
$19.98
$10.99
P/E Ratio
$398.10
$85.72
Revenue Growth
N/A
13.67
52 Week Low
$60.50
$81.09
52 Week High
$157.01
$132.60

Technical Indicators

Market Signals
Indicator
LSCC
INCY
Relative Strength Index (RSI) 42.85 48.53
Support Level $110.97 $121.61
Resistance Level $124.30 $131.70
Average True Range (ATR) 3.88 3.20
MACD 0.28 -0.64
Stochastic Oscillator 41.16 19.86

Price Performance

Historical Comparison
LSCC
INCY

About LSCC Lattice Semiconductor Corporation

Lattice Semiconductor Corp is a developer of semiconductor technology that it distributes through products, solutions, and licenses. The company reaches its customers through consumer, communications, and industrial markets. The company has one operating segment namely the core Lattice business that includes silicon-based and silicon-enabling products, evaluation boards, development hardware, and related intellectual property licensing, services, and sales. The products of the company are offered globally; and, the majority of sales are derived from customers in Asia. It also has its presence in Americas and Europe.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: